Drug Discovery

CYBIN signs agreement to acquire Adelia Therapeutics

Cybin, a life sciences company focused on psychedelic pharmaceutical therapies, today announced the signing of a definitive agreement to acquire 100% of the shares in Adelia Therapeutics Inc. (“Adelia”) for up to CDN$20,161,575 (approximately $15.75m) in an all-stock transaction (the “Transaction”).

Syros acquires clinical-stage drug candidate for acute promyelocytic leukemia

Syros Pharmaceuticals, a leader in the development of medicines that control the expression of genes, today announced that it has acquired from Orsenix, LLC (Orsenix) all of its assets related to SY-2101, formerly known as ORH-2014, a novel oral form of arsenic trioxide (ATO).

Janssen acquires rights to Hemera’s investigational eye-disorder gene therapy

Janssen Pharmaceuticals, a part of Johnson & Johnson, has acquired rights to investigational eye-disorder gene therapy called HMR59 from Hemera Biosciences for an undisclosed sum.

Biogen and Sage Therapeutics to jointly develop therapies in depression and movement disorders

Biogen has entered into a $1.525bn worth deal with Sage Therapeutics for the development and commercialisation of breakthrough therapies in depression and movement disorders.

Telix Pharmaceuticals acquires Swiss-German biotechnology company TheraPharm

Telix Pharmaceuticals announces it has entered into an agreement with Scintec Diagnostics to acquire TheraPharm GmbH (‘TheraPharm’), a Swiss-German biotechnology company developing innovative diagnostic and therapeutic solutions in the field of hematology.

HiFiBiO partners with Pharmsynthez and IBCh to develop and commercialise SARS-CoV-2 neutralising antibody in Russia

HiFiBiO Therapeutics announced a partnership with Russian pharmaceutical company, Pharmsynthez PJSC and Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry RAS (IBCh).

Merck to buy biopharmaceutical firm OncoImmune for $425m

Merck, through a subsidiary, has agreed to acquire clinical-stage biopharmaceutical company OncoImmune for an upfront cash payment of $425m.

Novartis secures exclusive rights for potential acute respiratory distress syndrome cell therapy

Novartis announced that it entered into an exclusive worldwide license and collaboration agreement with Mesoblast to develop, commercialize and manufacture remestemcel-L for the treatment of acute respiratory distress syndrome (ARDS), including that associated with COVID-19.

Rilzabrutinib granted FDA fast track designation for treatment of immune thrombocytopenia

The US Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to the oral investigational Bruton’s tyrosine kinase (BTK) inhibitor, rilzabrutinib, which has the potential to be the first BTK inhibitor for the treatment of immune thrombocytopenia (ITP).